Flexion Therapeutics Inc. (NASDAQ:FLXN) announced that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. Flexion Therapeutics Inc. (NASDAQ:FLXN) shares after opening at $12.50 moved to $12.50 on last trade day and at the end of the day closed at $11.85. Company price to cash ratio as 8.81. Flexion Therapeutics Inc. (NASDAQ:FLXN) showed a negative weekly performance of -12.68%.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report top-line results from the company’s 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares fell -8.14% in last trading session and ended the day on $4.74. NYMX return on equity ratio is recorded as 90.50% and its return on assets is -387.90%. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) yearly performance is -7.96%.
BioLife Solutions Inc. (NASDAQ:BLFS) a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues announced preliminary revenue of $2 million for the first quarter of 2014. Proprietary product revenue shipments were $1.13 million, representing 71% growth over the same period in 2013. BioLife Solutions Inc. (NASDAQ:BLFS) shares moved down -4.30% in last trading session and was closed at $2.89, while trading in range of $2.82 – $3.03. BioLife Solutions Inc. (NASDAQ:BLFS) year to date (YTD) performance is -65.60%.
On April 23, 2014, Spherix Incorporated (NASDAQ:SPEX) filed with the Delaware Secretary of State a Certificate of Elimination eliminating its Series B Convertible Preferred Stock, Series E Convertible Preferred Stock and Series F Convertible Preferred Stock (collectively, the “Preferred Shares”) and returning them to authorized but undesignated shares of the Company’s preferred stock. None of the Preferred Shares were outstanding. Spherix Inc. (NASDAQ:SPEX) weekly performance is -13.74%. On last trading day company shares ended up $1.57. Spherix Inc. (NASDAQ:SPEX) distance from 50-day simple moving average (SMA50) is -56.42%. Analysts mean target price for the company is $1.00.